AstraZeneca COVID-19 Vaccine Trial Volunteer Showed Symptoms Of Rare Neurological Disorder

AstraZeneca Plc CEO Pascal Soriot said that a person experiencing symptoms related to a rare neurological disorder caused its global COVID-19 vaccine trials to pause. The trial participant, a woman in the United Kingdom, suffered symptoms consistent with a spinal inflammatory disorder called transverse myelitis. The vaccine trial was also halted earlier in July after a person suffered neurological symptoms, diagnosed as multiple sclerosis.

Read all